Zalifrelimab is under clinical development by Agenus and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zalifrelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AGEN-1884 (zalifrelimab) is under development for the treatment of pancreatic ductal adenocarcinoma, metastatic soft tissue sarcomas, solid tumors, metastatic angiosarcoma, non-small cell lung cancer (second line therapy), cervical cancer, advanced cutaneous squamous cell carcinoma, melanoma, non-muscle invasive bladder cancer, prostate cancer and lymphoma. It acts by targeting CTLA-4. The drug candidate is a lead compound and checkpoint modulator antibody. It is administered through intravenous and intravesical route. The drug candidate is based on the retrocyte display technology. It was also under development for the treatment of non-small cell lung cancer (first line therapy).
Agenus, formerly, Antigenics, is a clinical-stage immuno-oncology company that discovers, develops and commercializes immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company’s pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company’s technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Zalifrelimab’s drug-specific PTSR and LoA scores, buy the report here.